The Panacea Corporation first registered as a Brazilian company in 1985, having successfully leased large tracts of rainforest land from the federal government for research purposes.

In 1987, Panacea announced a cure for HIV. An intensive three-month outpatient treatment procedure resulted in complete eradication of the virus in 88% of patients; a second round of treatment increased that rate to 96%. By 1990, Panacea clinics were in 74 countries and all fifty of the United States - anywhere that could grant regulatory approval fast enough.

In 1992, Panacea announced a preventative treatment against several forms of cancer. The four-hour chemotherapy procedure involved intra-arterial and peritoneal injections, destroying nascent stage 0 and stage 1 carcinomas in every area of the body other than the brain, with virtually no side effects in healthy patients. Marketed as Cancer Cleansing, the product was soon covered by all major insurers. By 1998, cancer diagnosis saw its first major drop in decades: patients who had the Cleansing at least once were more than 80% less likely to be diagnosed with malignant carcinoma.

In 1995, Panacea announced trials on eight new vaccines: malaria, dengue, influenza A, rhinovirus A, and four unknown coronaviruses (considered to be at high risk of migrating from animals to humans, as influenza does). Six of the viruses were approved for regulatory testing by 1998; most notably, the influenza A vaccine protected against all strains of human flu for five years.

If you encounter this story on Amazon, note that it's taken without permission from the author. Report it.

(The rhinovirus A vaccine was considered a failure as it would require a booster every two years. The vaccine derived from the bat coronavirus was discontinued as unnecessary, although the swine-, rodent-, and avian-derived vaccines were seen as valuable.)

Deaths from malaria and dengue dropped precipitously in the late 90s and early 00s under the widespread administration of the new vaccines.

2005 saw the global roll-out of Mind Refresh, an overnight treatment that reversed the early symptoms of Altzheimer’s disease. One treatment per year was sufficient to reduce or eliminate early dementia symptoms in 87% of patients. Panacea also published research identifying other causes of dementia that could be addressed separately from their procedure.

From its founding, The Panacea Corporation had remained a closely-held concern, steered by a Board of Directors made up solely of members of the enigmatic Fernando family. Only the CEO, Claudete Fernando, acted as a public face and voice for the company.

But in 2010, despite their massive wealth and influence internationally, The Panacea Corporation was facing a difficult decision. The world was changing, and some of the Board began to believe it was time for them to go public.

It was a question, not of economics, but of image. And for this question they called in an expert.